SEMAGLUTIDE

Dose per Vial/Pen

Latest Research

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

2026 Apr-Jun

Gupta AK, Teasell EM, Economopoulos V, Mirmirani P

Open

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

2026 Apr 17

Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR, Meira Filho LF, Jones EP, Batchek D, Khandpekar S, Patel R, Awkal B, Pape A, Bahna M, Zamboni M, Prado CM

Open

Correction: Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.

2026 Apr 17

Wang W, Pang M, Zhang Y, Hou S, Xia Y, Shi Y, Zhang X, Wang Y

Open

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.

2026 Apr 17

Engström A, Svanström H, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, Hveem K, Jonasson C, Melbye M, Ueda P, Pasternak B

Open

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.

2026 Apr 17

Zaccardi F, Aroda VR, Arslan EG, Bardtrum L, Goldney J, Ising E, Priyadarshini P, Slater T, Davies MJ

Open

Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.

2026 Apr 17

Chen SC, Liu KW, Huang YN, Meyerowitz-Katz G, Su PH

Open

Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.

2026 Apr 17

Kassab J, Drazner MH, Thibodeau JT

Open

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.

2026 Apr 16

Lu Y, Chen J, Guo Y, Ding H, Liu YL, Van Name MA, Sharifi M, Lu Y, Chen Y

Open

Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis.

2026 Apr 16

Smith JE, Garbaccio NC, Mehdizadeh M, Schonebaum DI, Foster L, Cordero JJ, Lin SJ

Open

Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

2026 Apr 15

Gunasekaran P, Inban P, Agrawal A, Thai A, Aravazhi PS, Tariq H, Prajjwal P, John J

Open